Ruxolitinib Tablet bulk supplier for pharma manufacturers

Ruxolitinib Tablet 5mg, 15mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 5mg, 15mg

Reference Brands: Jakafi

Ruxolitinib is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production).15

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ruxolitinib Tablet? List it or send an offer →

Product Description:

-Ruxolitinib tablets are regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in compliance with GMP standards. In the US, FDA approval involved extensive clinical validation, safety assessments, and GMP compliance. In the EU, CE marking certifies conformity with MDR standards. These formulations undergo validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical trial data, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring regional compliance guarantees access to high-quality ruxolitinib tablets, supporting the effective management of myeloproliferative disorders and other hematologic conditions worldwide, enhancing patient outcomes.

Ruxolitinib Tablet — third party manufacturing & bulk supply

Ruxolitinib Tablet 5mg, 15mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ruxolitinib Tablet is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ruxolitinib Tablet listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ruxolitinib Tablet →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Ruxolitinib Tablet is listed as Tablets in 5mg, 15mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Ruxolitinib Tablet is referenced against Jakafi. Reference brands are shown for identification only and remain the property of their respective trademark owners.